JOVIC, Gordana
 Distribuzione geografica
Continente #
NA - Nord America 2.853
EU - Europa 1.466
AS - Asia 1.252
SA - Sud America 178
AF - Africa 40
OC - Oceania 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 5.792
Nazione #
US - Stati Uniti d'America 2.792
SG - Singapore 455
GB - Regno Unito 319
CN - Cina 286
IT - Italia 274
SE - Svezia 204
IE - Irlanda 190
VN - Vietnam 131
HK - Hong Kong 128
DE - Germania 127
BR - Brasile 126
RU - Federazione Russa 72
FI - Finlandia 68
UA - Ucraina 63
BD - Bangladesh 57
FR - Francia 51
TR - Turchia 39
IN - India 37
CA - Canada 33
LT - Lituania 22
BG - Bulgaria 21
AR - Argentina 19
KR - Corea 19
ID - Indonesia 14
NL - Olanda 14
MX - Messico 13
IQ - Iraq 12
ZA - Sudafrica 11
AE - Emirati Arabi Uniti 10
JP - Giappone 10
EC - Ecuador 9
CO - Colombia 8
ES - Italia 8
ET - Etiopia 8
PH - Filippine 8
PK - Pakistan 7
EG - Egitto 6
PL - Polonia 6
CL - Cile 5
MY - Malesia 5
SA - Arabia Saudita 5
IR - Iran 4
JO - Giordania 4
KE - Kenya 4
PT - Portogallo 4
RS - Serbia 4
SN - Senegal 4
UZ - Uzbekistan 4
AL - Albania 3
BE - Belgio 3
DO - Repubblica Dominicana 3
PY - Paraguay 3
TW - Taiwan 3
VE - Venezuela 3
AU - Australia 2
BO - Bolivia 2
CR - Costa Rica 2
GR - Grecia 2
HU - Ungheria 2
IL - Israele 2
LB - Libano 2
MA - Marocco 2
PA - Panama 2
PR - Porto Rico 2
TH - Thailandia 2
UY - Uruguay 2
AO - Angola 1
AT - Austria 1
AZ - Azerbaigian 1
BB - Barbados 1
BY - Bielorussia 1
BZ - Belize 1
CI - Costa d'Avorio 1
CY - Cipro 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
DM - Dominica 1
GT - Guatemala 1
HN - Honduras 1
KH - Cambogia 1
KY - Cayman, isole 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LV - Lettonia 1
ME - Montenegro 1
NG - Nigeria 1
NO - Norvegia 1
OM - Oman 1
PE - Perù 1
QA - Qatar 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
ST - Sao Tome e Principe 1
TJ - Tagikistan 1
TN - Tunisia 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 5.792
Città #
Singapore 311
Ashburn 278
Santa Clara 248
Fairfield 219
Southend 201
Dublin 188
Chandler 182
Woodbridge 156
Houston 135
San Jose 130
Hong Kong 120
Dearborn 118
Nyköping 109
Jacksonville 100
Beijing 91
Seattle 86
Cambridge 81
Wilmington 71
New York 69
Ann Arbor 68
London 55
Los Angeles 54
Council Bluffs 51
Helsinki 45
Ho Chi Minh City 40
Milan 38
Chicago 34
Hanoi 30
Munich 27
San Diego 27
The Dalles 26
Modena 25
Izmir 24
Princeton 22
Eugene 19
Hefei 19
Sofia 19
Rome 18
Lauterbourg 17
Moscow 16
Salt Lake City 15
Shanghai 15
Dallas 13
Jakarta 13
Seoul 13
Denver 12
Dong Ket 12
Palermo 12
Des Moines 11
Lansdale 11
Buffalo 10
Phoenix 10
Da Nang 9
Guangzhou 9
Turku 9
York 9
Brooklyn 8
Columbus 8
Orem 8
Tampa 8
Tokyo 8
Atlanta 7
Bologna 7
Bremen 7
Chengdu 7
Chennai 7
Stockholm 7
Frankfurt am Main 6
Montreal 6
Toronto 6
Baghdad 5
Boardman 5
Elk Grove Village 5
Guayaquil 5
Johannesburg 5
Kunming 5
Miami 5
Mumbai 5
Nanjing 5
Naples 5
Porto Alegre 5
Redondo Beach 5
São Paulo 5
Tulsa 5
Warsaw 5
Amman 4
Amsterdam 4
Ankara 4
Bari 4
Belo Horizonte 4
Charlotte 4
Dakar 4
Falls Church 4
Gallarate 4
Hải Dương 4
Kyiv 4
Norwalk 4
Ottawa 4
Redwood City 4
Rio de Janeiro 4
Totale 3.985
Nome #
Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management 428
Prognostic value of Dworak grade of regression (GR) in patients with rectal carcinoma treated with preoperative radiochemotherapy 407
Helicobacter pylori infection andchronic immune thrombocytopenic purpura: long-term results of bacteriumeradication and association with bacterium virulence profiles 399
Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancer. 382
MODULAZIONE DELL’ESPRESSIONE DI BIOMARCATORI E PROGNOSI IN PAZIENTI AFFETTE DA CARCINOMA MAMMARIO OPERABILE SOTTOPOSTE A CHEMIOTERAPIA PREOPERATORIA 373
Letrozole Versus Letrozole Plus Lapatinib (GW572016) in Hormone-Sensitive, HER2-Negative Operable Breast Cancer: A Double-Blind, Randomized Phase II Study with Biomarker Evaluation (EGF109077-LAP107692/LETLOB) 371
A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy 371
CHER LOB Trial: Preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer--Safety report as per Independent Data Monitoring Committee (IDMC) and preliminary activity data 320
Prognostic and Predictive Value of Baseline and Posttreatment Molecular Marker Expression in Locally Advanced Rectal Cancer Treated With Neoadjuvant Chemoradiotherapy 314
Middle turbinate preservation versus middle turbinate resection in endoscopic surgical treatment of nasal polyposis 307
Preoperative chemotherapy plus lapatinib or trastuzumab or both in Her2 positive operable breast cancer. EGF109085-LAP106988/CHERLOB Trial. 305
PROLIFERATION AND APOPTOSIS BEFORE AND AFTER PRIMARY SYSTEMIC THERAPY FOR OPERABLE BREAST CANCER 273
Preliminary safety data of preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer 267
Biomarker expression and survival after primary chemotherapy for breast cancer. 245
CHER-LOB: PREOPERATIVE CHEMOTHERAPY PLUS TRASTUZUMAB, LAPATINIB OR BOTH IN HER2-POSITIVE OPERABLE BREAST CANCER – PRELIMINARY SAFETY REPORT WITH FOCUS ON CARDIAC TOLERABILITY 239
COMPARISON OF HER-2 STATUS IN PRIMARY BREAST CANCER AND METASTATIC SITES: RESULTS FROM A SINGLE INSTITUTION ANALYSIS 237
LET-LOB: preoperative letrozole plus lapatinib or placebo in hormone-receptor positive HER2 negative operable breats cancer. Preliminary report of activity and cardiac tolerability 214
CHEMOTHERAPY-INDUCED MODULATION OF BIOMARKERS EXPRESSION IN PRIMARY BREAST CANCER PATIENTS TREATED WITH PREOPERATIVE CHEMOTHERAPY 188
Final results of a phase II, double blind, placebo controlled, randomized trial of preoperative chemotherapy +/- gefitinib with biomarker evaluation in operable breast cancer 180
Totale 5.820
Categoria #
all - tutte 19.724
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 19.724


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202132 0 0 0 0 0 0 0 0 0 0 0 32
2021/2022394 7 52 59 23 10 32 24 13 39 17 75 43
2022/2023679 88 82 32 56 45 59 21 36 215 4 8 33
2023/2024379 18 22 22 29 81 45 23 55 16 9 33 26
2024/2025891 28 21 10 79 169 151 52 59 121 39 61 101
2025/20261.887 102 47 109 229 409 116 215 80 176 196 138 70
Totale 5.820